Speeding up its push into the Latin American cervical cancer screening market

AIDOT Co., Ltd. (AIDOT, CEO Jaehoon Jung), an AI medical imaging analysis company, has recorded its first sales in Peru’s private healthcare market with its AI-powered digital colposcope (a device used for cervical examination), Cerviray AI, accelerating its expansion into Latin America.

AIDOT said it has steadily expanded its business presence across key Latin American countries, including Mexico, Chile, Honduras, and Bolivia. With its first commercial sales now generated in Peru’s private sector, the company said its business performance in the region is becoming more tangible.

According to the company, demand for digital transformation in cervical cancer screening is growing rapidly across Latin America.

AIDOT’s Cerviray is described as the world’s first—and the only product in Korea—to offer automatic cervical lesion detection for cervical cancer screening, along with four-tier diagnostic results (Normal, CIN1, CIN2-3, CIN3+) and AI-based automatic report generation.

The company says these features give it a clear technological edge in local markets.

In particular, AIDOT expects Cerviray’s on-device design—allowing stable operation even in areas with unreliable network connectivity—to be a strong advantage. The company also noted that, compared with conventional equipment, the system does not require a complicated installation process, making it easier to adopt and operate at private medical institutions in Peru and other Latin American countries.

An AIDOT official said, “The start of commercial sales in Peru’s private market is an important milestone that shows our Latin America expansion strategy is delivering visible results.” The official added, “With our business footprint now expanded from Mexico, Chile, Honduras, and Bolivia to Peru, we will step up efforts to lead the cervical cancer screening market across Latin America.”

The official continued, “Based on the references and sales performance we build in the Latin American market, we plan to further strengthen our leadership in the global cervical cancer screening market.”

Korea Economic TV / 2026-02-25 / Vice Bureau Chief Yang Jae-jun